 Pfizer Inc. PFE, -0.36 and BioNTech SE BNTX, 0.21 said Monday that they formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains. 